Core Viewpoint - The company, Brain Dynamics Aurora-B (06681), has seen its stock price increase by over 5%, currently trading at 6.51 HKD with a transaction volume of 48.33 million HKD, following the announcement of its participation in a significant national technology project focused on the prevention and treatment of cognitive disorders related to intracranial atherosclerotic stenosis [1] Group 1: Project Involvement - The company’s wholly-owned subsidiary, Smart Genius Technology, is a key collaborator in the national major science and technology project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases" [1] - The project specifically addresses the challenges in diagnosing cognitive disorders caused by intracranial atherosclerotic stenosis (ICAS) and aims to establish a deep reasoning model and a comprehensive management system for early disease screening, risk assessment, and intervention tools [1] Group 2: Technological Development - As a core technology unit, the company will be responsible for the development of the deep reasoning model related to cognitive disorders caused by ICAS and the construction of a digital diagnosis and treatment platform [1] - The project has recently been officially launched, indicating a significant step forward in the company's technological capabilities and contributions to the healthcare sector [1] Group 3: Collaboration and Recognition - Smart Genius Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has successfully applied for the establishment of the "Beijing Key Laboratory of Digital Medical for Cognitive Disorders," which has also been officially approved [1] - This collaboration highlights the company's commitment to advancing research and development in the field of cognitive health and its strategic partnerships with leading medical institutions [1]

Core Viewpoint - Brainstorm Aurora-B (06681) has seen a stock price increase of over 5%, currently trading at 6.18 HKD with a transaction volume of 16.66 million HKD, following the announcement of its participation in a significant national technology project focused on the prevention and treatment of various diseases, including cognitive disorders related to intracranial atherosclerosis [1] Group 1: Company Developments - The company announced that its wholly-owned subsidiary, Beijing Zhijingling Technology Co., Ltd. (Zhijingling Technology), is a key partner in the national technology major project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases" [1] - The project, which has recently been officially launched, aims to address diagnostic challenges related to cognitive disorders associated with intracranial atherosclerosis (ICAS) [1] - Zhijingling Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has also successfully established the "Beijing Key Laboratory of Digital Medical for Cognitive Disorders" [1] Group 2: Project Focus and Objectives - The national technology major project focuses on the diagnostic challenges of ICAS-related cognitive disorders, leveraging interdisciplinary advantages for systematic research [1] - Key objectives include the establishment of an assessment technology system for ICAS-related cognitive disorders and the development of a deep reasoning predictive model to provide early screening, risk assessment, prevention, and intervention tools [1] - The project aims to create a comprehensive management system for ICAS-related cognitive disorders, ensuring a closed-loop management approach across various scenarios [1]